BioSpace News Archive

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR) today announced the U.S. Food and Drug Administration (FDA) has granted a dermal carcinogenicity (CARC) waiver for TMB-001, a topical isotretinoin formulated using the Company’s patented IPEG™ delivery system.

Cardiff Oncology, Inc. announced that company management will participate in a company presentation and 1x1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 7-9, 2023.

Waters Corporation and Sartorius announced a new collaboration to develop integrated analytical solutions for downstream biomanufacturing, expanding their joint agreement that began with upstream bioprocessing analytics.

Conformal Medical, Inc., a medical device company developing next-generation left atrial appendage occlusion technology, announced the successful completion of its Series D funding round, raising a total of $35 million.

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced the presentation of new 15-month safety and efficacy data from its ongoing Phase 1/2A clinical trial evaluating the safety, tolerability, and signal of efficacy of Radspherin® in patients with peritoneal carcinomatosis from colorectal cancer at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Thermo Fisher Scientific is showcasing new mass spectrometry and chromatography instruments, software and workflows that enable customers to unlock deeper analytical insights, improve productivity and accelerate biological discovery.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, announced the appointment of Rochelle Chaiken, M.D., as Chief Medical Officer.

OrsoBio, Inc. today announced completion of the second cohort of subjects in an ongoing Phase 1 trial of TLC-6740, a liver-targeted mitochondrial protonophore.

Ascentage Pharma announced that it has released updated results from a Phase II study of MDM2-P53 inhibitor, alrizomadlin, in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that had failed immuno-oncologic drugs in a Poster Presentation at the American Society of Clinical Oncology Annual Meeting.

RadNet, Inc. announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Jefferies 2023 Global Healthcare Conference on Thursday, June 8, 2023 at 3:00 p.m. Eastern Time.